- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Intravenous vs Oral Iron not tied with increased CKD Risk individuals with normal kidney function
Intravenous (IV) vs oral iron therapy is not associated with a higher risk for new-onset chronic kidney disease (CKD) among individuals with normal kidney function and no proteinuria, investigators reported at the American Society of Nephrology's Kidney Week 2022 conference in Orlando, Florida
Parenteral (IV) iron is effective in treating iron deficiency, but there are concerns about its potential nephrotoxicity. However, little is known about the long-term comparative renal safety of oral vs IV iron in patients with normal kidney function. We aimed to investigate the association of oral vs IV iron with the incidence of new onset chronic kidney disease (CKD).
They identified 94,931 incident new users of iron replacement therapy (N=91,945 on oral and 2,986 on IV iron) from 2004-2018 in a large national cohort of US Veterans. We used clinical trial emulation methods including propensity score (PS) matching to account for differences in key baseline characteristics and limited the cohort to patients with eGFR >60 ml/mi/1.73m2 and urine albumin creatinine ratio (UACR) <30 mg/g. We examined the association of oral vs IV iron with the incidence of eGFR <60 ml/min/1.73m2 and UACR >30 mg/g (both defined as two values at least 90 days apart) using competing risk regression.
The result:
- In the PS matched cohort there were 1,029 patients on oral and 1,043 on IV iron with eGFR ≥60 ml/min/1.73m2 and UACR <30 mg/g at baseline.
- Their characteristics were well balanced, with an overall mean (SD) age of 66±12 years, 92% male, 75% white, and baseline eGFR, hemoglobin and ferritin levels of 90±18 ml/min/1.73m2, 9.7±1.8 g/dL and 34 µg/L, respectively.
- There were 370 cases of incident GFR <60 and 251 cases of incident albuminuria over a median follow-up of 1.8 years.
- IV (vs oral) iron therapy was associated with similar risk of incident eGFR <60 and incident albuminuria
In this large national cohort of patients with baseline normal kidney function and no proteinuria, IV iron therapy was not associated with higher risk of incident CKD when compared to oral iron.
Reference:
Shrestha P, Paul S, Sumida K, et al. Association of parenteral vs. oral iron therapy with incident CKD. Presented at: Kidney Week 2022; November 3-6, Orlando, Florida. Abstract TH-PO682.
Keywords:
Shrestha P, Paul S, Sumida K, Intravenous (IV) vs oral iron therapy is not associated with a higher risk for new-onset chronic kidney disease (CKD) among individuals with normal kidney function and no proteinuria, investigators reported at the American Society of Nephrology's Kidney Week 2022 conference in Orlando, Florida
Parenteral (IV) iron is effective in treating iron deficiency, but there are concerns about its potential nephrotoxicity. However, little is known about the long-term comparative renal safety of oral vs IV iron in patients with normal kidney function. We aimed to investigate the association of oral vs IV iron with the incidence of new onset chronic kidney disease (CKD).
They identified 94,931 incident new users of iron replacement therapy (N=91,945 on oral and 2,986 on IV iron) from 2004-2018 in a large national cohort of US Veterans. We used clinical trial emulation methods including propensity score (PS) matching to account for differences in key baseline characteristics and limited the cohort to patients with eGFR >60 ml/mi/1.73m2 and urine albumin creatinine ratio (UACR) <30 mg/g. We examined the association of oral vs IV iron with the incidence of eGFR <60 ml/min/1.73m2 and UACR >30 mg/g (both defined as two values at least 90 days apart) using competing risk regression.
The result:
- In the PS matched cohort there were 1,029 patients on oral and 1,043 on IV iron with eGFR ≥60 ml/min/1.73m2 and UACR <30 mg/g at baseline.
- Their characteristics were well balanced, with an overall mean (SD) age of 66±12 years, 92% male, 75% white, and baseline eGFR, hemoglobin and ferritin levels of 90±18 ml/min/1.73m2, 9.7±1.8 g/dL and 34 µg/L, respectively.
- There were 370 cases of incident GFR <60 and 251 cases of incident albuminuria over a median follow-up of 1.8 years.
- IV (vs oral) iron therapy was associated with similar risk of incident eGFR <60 and incident albuminuria
In this large national cohort of patients with baseline normal kidney function and no proteinuria, IV iron therapy was not associated with higher risk of incident CKD when compared to oral iron.
Reference:
Shrestha P, Paul S, Sumida K, et al. Association of parenteral vs. oral iron therapy with incident CKD. Presented at: Kidney Week 2022; November 3-6, Orlando, Florida. Abstract TH-PO682.
Keywords:
Shrestha P, Paul S, Sumida K, Association, parenteral, oral, iron, therapy, incident CKD, Kidney Week 2022, parenteral, oral, iron, therapy, incident CKD, Kidney Week 2022
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751